Michael Davidson Sells 58,253 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CEO Michael Davidson sold 58,253 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $35.30, for a total transaction of $2,056,330.90. Following the transaction, the chief executive officer directly owned 459,859 shares in the company, valued at approximately $16,233,022.70. This represents a 11.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

NewAmsterdam Pharma Trading Up 3.4%

NASDAQ:NAMS opened at $35.46 on Friday. NewAmsterdam Pharma Company N.V. has a 12 month low of $14.06 and a 12 month high of $42.00. The stock has a market capitalization of $4.08 billion, a price-to-earnings ratio of -20.50 and a beta of 0.06. The firm has a fifty day simple moving average of $34.06 and a two-hundred day simple moving average of $32.95.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings data on Wednesday, February 18th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.23). The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.92 million. NewAmsterdam Pharma had a negative return on equity of 26.67% and a negative net margin of 906.22%. Equities analysts predict that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

NAMS has been the topic of a number of research reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of NewAmsterdam Pharma in a research report on Thursday, February 19th. Needham & Company LLC upped their price objective on shares of NewAmsterdam Pharma from $46.00 to $48.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Royal Bank Of Canada raised their price objective on shares of NewAmsterdam Pharma from $44.00 to $47.00 and gave the company an “outperform” rating in a research note on Wednesday, January 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Thursday, January 22nd. Finally, Leerink Partners restated an “outperform” rating and issued a $55.00 target price on shares of NewAmsterdam Pharma in a report on Tuesday, January 6th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $46.55.

Institutional Investors Weigh In On NewAmsterdam Pharma

Institutional investors have recently made changes to their positions in the stock. Farther Finance Advisors LLC lifted its position in NewAmsterdam Pharma by 4,425.0% in the 4th quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock valued at $25,000 after acquiring an additional 708 shares in the last quarter. Mather Group LLC. bought a new position in shares of NewAmsterdam Pharma in the third quarter worth about $28,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in shares of NewAmsterdam Pharma during the 3rd quarter valued at approximately $30,000. Wells Fargo & Company MN increased its stake in shares of NewAmsterdam Pharma by 50.0% in the fourth quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock worth $32,000 after purchasing an additional 300 shares in the last quarter. Finally, Navalign LLC bought a new position in shares of NewAmsterdam Pharma in the fourth quarter worth about $46,000. Hedge funds and other institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.